Investigation of the Status of Immune Checkpoint Molecules in Meningiomas by Immunohistochemistry.

IF 0.9 4区医学 Q4 CLINICAL NEUROLOGY Turkish neurosurgery Pub Date : 2024-01-01 DOI:10.5137/1019-5149.JTN.43334-23.2

Ismail Saygin, Emel Cakir, Seher Nazli Kazaz, Ali Rıza Guvercin, Ilker Eyuboglu, Muserref Muge Ustaoglu

{"title":"Investigation of the Status of Immune Checkpoint Molecules in Meningiomas by Immunohistochemistry.","authors":"Ismail Saygin, Emel Cakir, Seher Nazli Kazaz, Ali Rıza Guvercin, Ilker Eyuboglu, Muserref Muge Ustaoglu","doi":"10.5137/1019-5149.JTN.43334-23.2","DOIUrl":null,"url":null,"abstract":"Aim: To investigate the status of immune checkpoint molecules (CTLA-4 and TIM-3) in meningiomas and thus contribute to the development of new personalized treatment strategies.Material and methods: We utilized 402 cases of meningioma for this study. New blocks were prepared using the tissue microarray method, and sections obtained from these blocks were immunohistochemically stained with CTLA-4 and TIM-3 antibodies. Subsequently, statistical analysis were performed.Results: Our findings revealed that CTLA-4 expression were observed in 25.1% of meningiomas. CTLA-4 expression and the number of expressing lymphocytes were found to be significantly higher in high-grade tumors and in those with brain invasion. Meningiomas with staining of immune cells with TIM-3 are 3.5%, and the tumor grade was correlated with the number of immune cells expressing TIM-3.Conclusion: Immune checkpoint molecules (CTLA-4 and TIM-3) with varying levels of expression can serve as prognostic and predictive biomarkers, as well as important targets for therapy. Drugs developed for CTLA-4 and TIM-3 molecules may prove to be more effective in treating meningiomas with high-grade, brain-invading, spontaneous necrosis, and macronucleolus.","PeriodicalId":23395,"journal":{"name":"Turkish neurosurgery","volume":"1 1","pages":"647-654"},"PeriodicalIF":0.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish neurosurgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5137/1019-5149.JTN.43334-23.2","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To investigate the status of immune checkpoint molecules (CTLA-4 and TIM-3) in meningiomas and thus contribute to the development of new personalized treatment strategies.

Material and methods: We utilized 402 cases of meningioma for this study. New blocks were prepared using the tissue microarray method, and sections obtained from these blocks were immunohistochemically stained with CTLA-4 and TIM-3 antibodies. Subsequently, statistical analysis were performed.

Results: Our findings revealed that CTLA-4 expression were observed in 25.1% of meningiomas. CTLA-4 expression and the number of expressing lymphocytes were found to be significantly higher in high-grade tumors and in those with brain invasion. Meningiomas with staining of immune cells with TIM-3 are 3.5%, and the tumor grade was correlated with the number of immune cells expressing TIM-3.

Conclusion: Immune checkpoint molecules (CTLA-4 and TIM-3) with varying levels of expression can serve as prognostic and predictive biomarkers, as well as important targets for therapy. Drugs developed for CTLA-4 and TIM-3 molecules may prove to be more effective in treating meningiomas with high-grade, brain-invading, spontaneous necrosis, and macronucleolus.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

用免疫组化方法研究脑膜瘤中免疫检查点分子的状况。

目的：彻底切除肿瘤是治疗脑膜瘤最有效的方法。然而，缺乏有效的药物治疗，尤其是无法手术的高级别脑膜瘤，会对患者的生存产生负面影响。我们旨在研究脑膜瘤中免疫检查点分子（CTLA-4和TIM-3）的状况，从而为开发新的个性化治疗策略做出贡献：本研究使用了402例脑膜瘤病例。采用组织微阵列方法制备新的组织块，并用 CTLA-4 和 TIM-3 抗体对这些组织块的切片进行免疫组化染色。随后进行统计分析：结果：我们的研究结果显示，25.1%的脑膜瘤存在 CTLA-4 表达。CTLA-4的表达和表达淋巴细胞的数量在高级别肿瘤和有脑侵犯的肿瘤中明显较高。免疫细胞TIM-3染色的脑膜瘤占3.5%，肿瘤分级与表达TIM-3的免疫细胞数量相关：结论：不同表达水平的免疫检查点分子（CTLA-4 和 TIM-3）可作为预后和预测生物标志物，也是重要的治疗靶点。针对CTLA-4和TIM-3分子开发的药物可能会对治疗高级别、侵袭大脑、自发性坏死和巨核细胞脑膜瘤更有效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Turkish neurosurgery 医学-临床神经学

CiteScore

1.50

自引率

12.50%

发文量

126

审稿时长

2 months

期刊介绍： Turkish Neurosurgery is a peer-reviewed, multidisciplinary, open access and totally free journal directed at an audience of neurosurgery physicians and scientists. The official language of the journal is English. The journal publishes original articles in the form of clinical and basic research. Turkish Neurosurgery will only publish studies that have institutional review board (IRB) approval and have strictly observed an acceptable follow-up period. With the exception of reference presentation, Turkish Neurosurgery requires that all manuscripts be prepared in accordance with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals.